Who are Lacosamide - rapid titration 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lacosamide - rapid titration 1, Lasosamide Oral Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lacosamide-rapid-titration-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lacosamide - rapid titration 2 — Competitive Intelligence Brief

Lacosamide - rapid titration 2 (Lacosamide - rapid titration 2) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant; sodium channel modulator. Area: Neurology.

marketed Anticonvulsant; sodium channel modulator Voltage-gated sodium channels; CRMP-2 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Lacosamide - rapid titration 2 (Lacosamide - rapid titration 2) — Seoul National University Hospital. Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lacosamide - rapid titration 2 TARGET	Lacosamide - rapid titration 2	Seoul National University Hospital	marketed	Anticonvulsant; sodium channel modulator	Voltage-gated sodium channels; CRMP-2
Lacosamide - rapid titration 1	Lacosamide - rapid titration 1	Seoul National University Hospital	marketed	Antiepileptic agent (sodium channel modulator)	Voltage-gated sodium channels (slow inactivation enhancer)
Lasosamide Oral Solution	Lasosamide Oral Solution	UCB BIOSCIENCES, Inc.	phase 3	Sodium channel modulator; Antiepileptic drug	Voltage-gated sodium channels (Nav)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant; sodium channel modulator class)

Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lacosamide - rapid titration 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/lacosamide-rapid-titration-2. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab